WHIPPANY, N.J., May 29, 2015 (GLOBE NEWSWIRE) -- Pazoo, Inc. (OTC Pinks:PZOO) (German WKN#: A1J3DK), is pleased to report that it has formed a 100% wholly owned subsidiary called CannabisKing Distribution LLC. CannabisKing has been formed to be the marketing and sales agent for the distribution of non-controlled hemp products throughout the USA. Non-controlled hemp products are the items utilized by the industry that support grow facilities, infusion companies and dispensaries.
Through Pazoo's two other subsidiary companies, strong relationships are already being forged with a large number of growers and other industry related enterprises. A plethora of product support related companies have taken note of this and have requested that Pazoo become a sales and distribution outlet for them. This is what led to the formation of CannabisKing.
CEO David Cunic states, "We are very happy and thrilled with adding another subsidiary company. CannabisKing Distrubution LLC was formed out of demand by industry suppliers. Part of this demand came through our social media presence, online presence, and by us attending numerous events and expositions. Many of these industry suppliers have already realized that Pazoo is poised to create the largest footprint throughout most of the country and they want access, through us, to our developing relationships as well."
In other news, Pazoo Inc.'s Nevada subsidiary M & A Associates, LLC is hosting a grand opening of their Las Vegas, Nevada, Testing Lab on Wednesday, June 3rd. The first part of Pazoo Fest will be held from 3:30 – 7:00PM at the laboratory in Las Vegas at 2009 Western Avenue and is an open house for everyone. The second half of Pazoo Fest has been set to begin at 6:00PM and will last until 10:00PM. Please RSVP by emailing your name and contact information to investor@pazoo.com to get your name on the list.
ABOUT PAZOO Inc.
Pazoo, Inc., is a company focused on health, wellness and safety. Our focus is to provide best-in-class laboratory testing of cannabis and cannabinoids to protect consumers from impurities, contaminants and other irregularities. Through our wholly-owned subsidiary, Harris Lee, and our partnership with MA & Associates, Pazoo provides industry-leading laboratory testing of cannabis. Harris Lee's and MA's license agreements with Steep Hill Labs, Inc. allows the Pazoo subsidiaries to use Steep Hill's top-rated testing protocols in select markets as we expand throughout the USA. Pazoo's subsidiaries are currently licensed to test cannabis in Nevada, Oregon and Colorado, with other states to come. Additionally, Pazoo delivers a comprehensive array of health and wellness information on its website www.pazoo.com.
ABOUT STEEP HILL LABS Inc.
Founded in California in 2008, Steep Hill is a science and technology firm that has become the industry leader in cannabis testing and analytics. With owned and licensed labs in four U.S. states and plans to add labs in New Mexico, Oregon and possibly Jamaica in 2015, Steep Hill is the largest cannabis lab network in the world. The company pioneered the first medical cannabis potency and microbiological contaminants testing methodology for use in California - the first state to legalize medical cannabis. Steep Hill has since developed a variety of revolutionary cannabis testing products, including QuantaCann™, QuantaCann2™ and GenKit™. Steep Hill provides expert consulting services to many states, countries and municipalities, and the company is developing proprietary genetic testing, mapping and trademark protection services for the industry as well.
Safe Harbor Statement:
This update includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as Pazoo, Inc. or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statement.